Selina J Chavda
Overview
Explore the profile of Selina J Chavda including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
23
Citations
239
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Galas-Filipowicz D, Chavda S, Gong J, Huang D, Khwaja A, Yong K
Front Oncol
. 2024 Apr;
14:1394393.
PMID: 38651147
Introduction: BCL-2 family proteins are important for tumour cell survival and drug resistance in multiple myeloma (MM). Although proteasome inhibitors are effective anti-myeloma drugs, some patients are resistant and almost...
2.
Popat R, Chavda S
Lancet Haematol
. 2023 Oct;
10(10):e788-e789.
PMID: 37793762
No abstract available.
3.
Cowan A, Ferrari F, Freeman S, Redd R, El-Khoury H, Perry J, et al.
Lancet Haematol
. 2023 Mar;
10(3):e203-e212.
PMID: 36858677
Background: Patients with precursors to multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or smouldering multiple myeloma on the basis of monoclonal protein concentrations or bone marrow...
4.
Leng H, Zhang H, Li L, Zhang S, Wang Y, Chavda S, et al.
Nat Commun
. 2022 Dec;
13(1):7868.
PMID: 36550101
Patients with multiple myeloma, an incurable malignancy of plasma cells, frequently develop osteolytic bone lesions that severely impact quality of life and clinical outcomes. Eliglustat, a U.S. Food and Drug...
5.
Yong K, Wilson W, De Tute R, Camilleri M, Ramasamy K, Streetly M, et al.
Lancet Haematol
. 2022 Dec;
10(2):e93-e106.
PMID: 36529145
Background: Standard-of-care treatment for patients with newly diagnosed multiple myeloma is bortezomib-based induction followed by high-dose melphalan and autologous haematopoietic stem-cell transplantation (HSCT) and lenalidomide maintenance. We aimed to evaluate...
6.
Bustoros M, Anand S, Sklavenitis-Pistofidis R, Redd R, Boyle E, Zhitomirsky B, et al.
Nat Commun
. 2022 Jun;
13(1):3449.
PMID: 35705541
Smoldering multiple myeloma (SMM) is a precursor condition of multiple myeloma (MM) with significant heterogeneity in disease progression. Existing clinical models of progression risk do not fully capture this heterogeneity....
7.
Ainley L, Camilleri M, Chavda S, McMillan A, Lee L, Popat R, et al.
Br J Haematol
. 2021 Nov;
196(6):e63-e66.
PMID: 34812509
No abstract available.
8.
Chan W, Howells L, Wilson W, Sanchez E, Ainley L, Chavda S, et al.
Br J Haematol
. 2021 Oct;
196(3):e21-e26.
PMID: 34632575
No abstract available.
9.
Richards H, Chavda S, Wilson W, Camilleri M, Cohen O, Horder J, et al.
Leuk Lymphoma
. 2021 Aug;
62(14):3544-3547.
PMID: 34348069
No abstract available.
10.
Chan W, Sanchez E, Chavda S, Lecat C, Ainley L, Xu K, et al.
Br J Haematol
. 2021 Jul;
194(5):857-861.
PMID: 34323287
No abstract available.